This compound is primarily utilized in the field of biomedical research, particularly in the development of targeted protein degradation technologies. It serves as a key component in Proteolysis-Targeting Chimeras (PROTACs), which are designed to selectively degrade disease-causing proteins within cells. By binding to both the target protein and an E3 ubiquitin ligase, it facilitates the ubiquitination and subsequent degradation of the protein via the proteasome pathway. This approach is especially promising in cancer research, where it can be used to eliminate oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, its application extends to neurodegenerative diseases and other conditions driven by aberrant protein activity, offering a novel therapeutic strategy.